Scribe Therapeutics Inc. SCTX
Set alert
At close · Oct 30
After hours · Oct 30, 7:55 PM ET
- YTD
- -18.71%
- 1 year
- -18.71%
- Open
- 17.00
- Prev close
- 17.44
- Mkt cap
- 291.93M
- Vol
- 480.71K
- Avg vol
- 367.98K
- EPS
- -3.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.77
- High
- 17.00
News
1 week ago fool.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Ark Invest added to three existing positions on Monday, all of them down sharply from recent highs.
2 weeks ago seekingalpha.com
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst
Scribe Therapeutics is initiated with a buy rating, targeting the in-vivo gene therapy market for cardiometabolic diseases with lead asset STX-1150. STX-1150 aims to provide durable, reversible PCSK9…
2 weeks ago benzinga.com
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
3 weeks ago benzinga.com
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of…
1 month ago defenseworld.net
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts
Scribe Therapeutics Inc. (NASDAQ: SCTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are covering the company, MarketBeat Ratings reports.…
1 month ago benzinga.com
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Scribe Therapeutics (NASDAQ:SCTX) with a Buy and maintains $60 price target.
-
1 month ago benzinga.com
Scribe Therapeutics Q3 EPS $(2.62) Misses $(1.05) Estimate, Sales $1.918M Miss $3.113M Estimate
Scribe Therapeutics (NASDAQ:SCTX) reported quarterly losses of $(2.62) per share which missed the analyst consensus estimate of $(1.05) by 149.52 percent. The company reported quarterly sales of…
1 month ago globenewswire.com
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting…
1 month ago benzinga.com
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
2 months ago globenewswire.com
Scribe Therapeutics to Participate in Upcoming Investor Conferences
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR…
2 months ago 247wallst.com
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More
Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that…
-
2 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $60
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Buy rating and announces Price Target of $60.
2 months ago benzinga.com
Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday
U.S. stocks mixed, Nasdaq falls 0.1%. Gap Inc shares rise 15.2% on strong earnings and raised guidance. Other big gainers include Elastic NV, Solstice Advanced Materials Inc, and Pagerduty Inc.
2 months ago benzinga.com
Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday
The text discusses recent gains in the stock market, particularly for companies like Napco Security Technologies and SuperX AI Technology. US stocks were mixed, with the Dow Jones index gaining 150…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday's regular session. The company's market cap stands at $125.2 million. BioVie (NASDAQ:BIVI) stock…
2 months ago benzinga.com
Deere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday
Dow Jones down 300 points, Deere & Co shares up 7.9% after beating earnings expectations. SCTX, SCSC, BTBT, MRVI, HIVE, AHG, TEM, MARA, LB also gain.
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers AIxCrypto Hldgs (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regular session. The market value of their outstanding shares is at $14.3 million. Amylyx Pharmaceuticals…
-
2 months ago benzinga.com
Wells Fargo Initiates Coverage On Scribe Therapeutics with Overweight Rating, Announces Price Target of $60
Wells Fargo analyst Yanan Zhu initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Overweight rating and announces Price Target of $60.
-
2 months ago benzinga.com
Leerink Partners Initiates Coverage On Scribe Therapeutics with Outperform Rating, Announces Price Target of $37
Leerink Partners analyst David Risinger initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Outperform rating and announces Price Target of $37.
-
2 months ago benzinga.com
Guggenheim Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $50
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Buy rating and announces Price Target of $50.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
3 months ago globenewswire.com
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR…
3 months ago globenewswire.com
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR…